



PRESS RELEASE • PRESS RELEASE • PRESS RELEASE

EUR 8 million capital increase successfully completed

- Total gross proceeds of 8,045,102.95 Euros
- 9,464,827 new shares issued
- Rights issue fully subscribed

Paris, June 22, 2016 – NEOVACS (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, is pleased to announce the successful completion of its capital increase with preferential subscription rights (PSRs), which took place June 1-22, 2016.

Neovacs is focused on clinical, preclinical and pharmaceutical development of IFN α Kinoid

As previously mentioned, the funds raised will enable the Company to strengthen its financial base and fund its future programmes. In particular, funds will be deployed for external costs related to the clinical and preclinical trials, the preparation, development and production of IFN α -K clinical lots in anticipation of a Korean market entry and the launch of phase III trial with the IFN α -K for the treatment of Lupus. The Company will also initiate a phase IIa study with IFN α Kinoid in Dermatomyositis with a part of the proceeds.

Miguel Sieler, CEO of Neovacs said:

"Following IND approval from the FDA in the United States, the signing of two important partnerships and the recent approval by the European authorities of our Phase IIa study in Dermatomyositis, Neovacs has achieved with this successful financing another milestone in the pursuit of its near-term objectives. I want to thank all of our individual and institutional shareholders for their confidence and support. The success of this financing, despite a challenging market environment, provides Neovacs the funds to continue to implement our development plan and thus increase the chances of success."

Subscription result and shares allocation

The demand for shares amounted to approximately 8.7 million euros, distributed as follows:

- 4 715 478 new shares were subscribed on an irreducible basis, representing 49.8% of the new shares to be issued;
- 1 360 061 new shares were requested and subscribed for excess shares, representing 14.4% of the new shares to be issued;
- 4 176 470 new shares were requested and subscribed to free title, representing 44.1% of the new shares to be issued.

Not for distribution, directly or indirectly in the United States, Canada, Australia and Japan.

Subscriptions to free title will only be partially allocated with a total of 3 389 288 new shares, of which 3 095 171 new shares are allocated to the guarantor investors, distributed among them proportionally to their subscription commitments.

Following the completion of this offering, Neovacs share capital will be of 6 388 758.30 euros, consisting of 42 591 722 shares.

The settlement June 24, 2016 and admission to trading on the Alternext Paris market of new shares are scheduled for June 27, 2016. The new shares will be immediately assimilated with existing shares and will be traded on Alternext Paris under the same listing (ISIN code FR0004032746).

The capital increase was led by Invest Securities as Lead Manager and Bookrunner.

A share capital increase eligible for the ISF-TEPA tax reduction

This share capital increase was eligible for the reduction on wealth tax (ISF) provided for by the "TEPA" law, as subscriptions in the share capital of a SME.

In order to obtain their tax certificate, the subscribers of new shares issued by Neovacs in the context of this share capital increase shall send to the address below a justificative document issued by their financial intermediary certifying their subscription to the operation:

Néovacs

3/5 impasse Reille
75014 Paris
neovacs@newcap.eu

The Company reminds that the tax reduction will only be possible for the ISF to be paid in 2017 and that such reduction is subject to the compliance to certain conditions by the subscriber, hence it is each subscriber's responsibility to verify that the eligibility criteria to this tax reduction apply to their personal situation.

Information available to the public

A prospectus approved by the AMF on May 31, 2016 under number 16-214, consisting of a reference document (*document de référence*) registered on May 13, 2016 under number R.16-046 and a Securities Note (including a summary), is available on the websites of Neovacs (www.neovacs.fr) and the AMF (www.amf-france.org).

About Neovacs

Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFN α -Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

Néovacs is eligible for the "PEA-PME" plan.

All information about Neovacs is available on the website: www.neovacs.fr

Not for distribution, directly or indirectly in the United States, Canada, Australia and Japan.

Contacts

Neovacs

Charlène Masson
+33 (0)1 53 10 93 00
cmasson@neovacs.com

Press / U.S. Inquiries – The Ruth Group

Joanna Zimmerman / Joseph Green
+1-646-536-7012 / 7013
zimmerman@theruthgroup.com / jgreen@theruthgroup.com

New Cap

Valentine Brouhot / Pierre Laurent
+33 (0)1 44 71 94 94
neovacs@newcap.eu

Investor Relations / Financial Communications Germany – MC Services

Raimund Gabriel
+49-89-21-02-28-30
raimund.gabriel@mc-services.eu

Invest Securities

Pascal Hadjedj / Sami Berhouma
Tél. : +33 (0)1 55 35 55 61 / +33 (0)1 44 88 77 86
phadjedj@invest-securities.com / sberhouma@invest-securities.com

Disclaimer

This press release and the information contained herein do not constitute either an offer to sell or purchase or the solicitation of an offer to sell or purchase the Neovacs new shares or preferential subscription rights, in any country whatsoever.

The diffusion of this press release in some jurisdictions may constitute a violation of applicable laws and regulations. People physically present in these jurisdictions in which this press release is distributed shall get informed about such restrictions and comply with them.

With respect to each Member State of the European Economic Area other than France (the “**Member State**”) which has implemented the directive 2003/71/EC, as amended, in particular by Directive 2010/73/EU and to the extent implemented in the Member State, (the “**Prospectus Directive**”), no action has been undertaken or will be undertaken to make an offer to the public of new shares or preferential subscription rights requiring a publication of a prospectus in any Member State. As a result, new shares or preferential subscription rights may only be offered in Member States pursuant to an exemption under the Prospectus Directive (article 3(2)).

Securities mentioned in this press release may not be offered or sold in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Neovacs does not intend to register any portion of the planned offer in the United States of America or to conduct a public offering of securities in the United States of America.

This press release is directed only at and is for distribution only to persons who (i) are “investment professionals” falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “**Order**”), (ii) are persons falling within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations etc.”) of the Order or (iii) are other persons to whom an invitation or inducement to engage in investment activity (within the meaning of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons in (i), (ii), and (iii) together being referred to as “**Relevant Persons**”). In the United Kingdom, this press release is directed to Relevant Persons and no persons other than Relevant Persons should use or rely on this press release. Any investment or investment activity to which this press release relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

Not for distribution, directly or indirectly in the United States, Canada, Australia and Japan.

The distribution of this press release in certain countries may constitute a violation of legal provisions in force. This press release may not be published, distributed or diffused, directly or indirectly, in Canada, Australia, or Japan.